METROPOLITAN LIFE INSURANCE CO/NY - CYTOMX THERAPEUTICS INC ownership

CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 129 filers reported holding CYTOMX THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
METROPOLITAN LIFE INSURANCE CO/NY ownership history of CYTOMX THERAPEUTICS INC
ValueSharesWeighting
Q1 2022$12,570
-74.6%
4,708
-58.9%
0.00%
-100.0%
Q4 2021$49,544
+46.5%
11,442
+72.2%
0.00%
Q3 2021$33,828
-71.8%
6,646
-64.9%
0.00%
-100.0%
Q2 2021$119,789
-5.2%
18,924
+15.7%
0.00%0.0%
Q1 2021$126,424
+333.7%
16,355
+267.5%
0.00%
Q4 2020$29,148
-69.6%
4,450
-69.2%
0.00%
-100.0%
Q3 2020$96,026
-21.2%
14,440
-1.3%
0.00%0.0%
Q2 2020$121,901
+81.1%
14,634
+66.8%
0.00%
+100.0%
Q1 2020$67,312
-32.3%
8,776
-26.7%
0.00%
-50.0%
Q4 2019$99,479
-27.8%
11,971
-35.9%
0.00%0.0%
Q3 2019$137,873
-9.5%
18,682
+37.5%
0.00%
-33.3%
Q2 2019$152,412
+18.1%
13,584
+13.1%
0.00%
+50.0%
Q1 2019$129,097
-36.6%
12,009
-10.9%
0.00%
-50.0%
Q4 2018$203,533
-14.8%
13,479
+4.4%
0.00%0.0%
Q3 2018$238,965
-99.9%
12,9170.0%0.00%
-20.0%
Q2 2018$295,283,000
+9.4%
12,917
+36.2%
0.01%
+25.0%
Q1 2018$269,849,000
+137578.1%
9,485
+2.0%
0.00%
+33.3%
Q4 2017$196,000
-37.2%
9,298
-45.9%
0.00%
+50.0%
Q3 2017$312,000
+17.3%
17,1760.0%0.00%0.0%
Q2 2017$266,000
-10.4%
17,1760.0%0.00%0.0%
Q1 2017$297,000
+57.1%
17,1760.0%0.00%
+100.0%
Q4 2016$189,000
-29.7%
17,1760.0%0.00%
-50.0%
Q3 2016$269,000
+53.7%
17,1760.0%0.00%
+100.0%
Q2 2016$175,00017,1760.00%
Other shareholders
CYTOMX THERAPEUTICS INC shareholders Q4 2020
NameSharesValueWeighting ↓
Aquilo Capital Management, LLC 524,763$7,924,0003.84%
Congress Park Capital LLC 123,311$1,862,0002.05%
Perceptive Advisors 2,911,715$43,588,0001.66%
RTW INVESTMENTS, LP 908,586$13,720,0001.28%
HAMILTON LANE ADVISORS LLC 68,753$1,038,0000.91%
HARBOURVEST PARTNERS LLC 79,193$1,196,0000.57%
SPHERA FUNDS MANAGEMENT LTD. 273,151$4,125,0000.46%
Exane Asset Management 50,000$755,000,0000.44%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 622,548$9,400,0000.38%
Cormorant Asset Management, LP 296,712$4,480,0000.36%
View complete list of CYTOMX THERAPEUTICS INC shareholders